What is Supernus Pharmaceuticals, Inc.'s Shariah compliance score?

Supernus Pharmaceuticals, Inc. (SUPN) has a Shariah compliance score of 84/100 (Grade: A, Very Good) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does Supernus Pharmaceuticals, Inc. pass AAOIFI screening?

Supernus Pharmaceuticals, Inc. (SUPN) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (SUPN: 1.6%), (3) interest-bearing deposits below 30% (SUPN: 4.5%), and (4) prohibited income below 5% (SUPN: 2.2%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Supernus Pharmaceuticals, Inc. stock?

Supernus Pharmaceuticals, Inc. (SUPN) has a non-permissible income ratio of 2.21%. Muslim investors should purify this percentage of any dividends received and capital gains realized from SUPN shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Supernus Pharmaceuticals, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Supernus Pharmaceuticals, Inc. (SUPN) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about SUPN's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is Supernus Pharmaceuticals, Inc. (SUPN) halal? Halal. Based on AAOIFI screening, Supernus Pharmaceuticals, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 84/100 (Grade: A).

SUPN: Is Supernus Pharmaceuticals, Inc. Halal?

Halal

Supernus Pharmaceuticals, Inc.

NASDAQHealthcareUS

$47.77

-1.35%

AvoidBorderlineClean

Purify ~2.2% of income

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 18, 2026

Very Good

Strong compliance across all metrics

84Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Passed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap1.6% / 30.0%

Compliance History

Halalnow
since Jun 2026
Not Halal
until the change above
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 18, 2026Fiscal: Q1 2026Source: EDGAR

Purify Your SUPN Dividends

2.2% non-compliant income

SUPN has 2.2% prohibited income. Calculate exactly how much of your dividends to donate.

Financial Overview

Market Cap

2.8B

Price

$47.77

Sector

Healthcare

Industry

Drug Manufacturers—Specialty & Generic

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track SUPN and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. (SUPN) halal to invest in?

Based on AAOIFI Standard 21 screening, Supernus Pharmaceuticals, Inc. (SUPN) is rated Halal with a compliance grade of A (Very Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did Supernus Pharmaceuticals, Inc. get a A compliance rating?

Supernus Pharmaceuticals, Inc. (SUPN) received a grade of A (Very Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 1.6% (limit 30%); interest-bearing deposits of 4.5% (limit 30%); prohibited income of 2.21% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Supernus Pharmaceuticals, Inc.'s Shariah verdict?

Supernus Pharmaceuticals, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Supernus Pharmaceuticals, Inc. re-screened for Shariah compliance?

Supernus Pharmaceuticals, Inc. (SUPN) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 18, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.